Compare JPMorgan Ultra Short Income ETF (JPST) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Ultra Short Income ETF vs Smith & Nephew plc — how do they compare? JPMorgan Ultra Short Income ETF trades at $50.49, while Smith & Nephew plc trades at $30.45 (market cap $12.64B). The key difference: Smith & Nephew plc pays a 2.57% dividend while JPMorgan Ultra Short Income ETF pays none. Which is the better fit depends on your goals.
| JPST | SNN | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $50.78 | $38.70 |
52-Week Low | $50.40 | $28.73 |
Market Cap | — | $12.64B |
Enterprise Value | — | $15.41B |
Dividend Yield | — | 2.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPST trades at $50.49, showing minimal daily movement with a slight decline of $0.01 (-0.02%). The technical outlook is bearish based on moving averages, while oscillators signal neutrality. Recent news highlights institutional interest, with Greenwood Gearhart LLC increasing its holdings by 9.6% as of July 2026. The ETF focuses on ultra-short income, offering a cash alternative with low duration risk, as noted in Seeking Alpha analysis from April 2026.
The outlook for JPST remains stable, appealing to risk-averse investors seeking capital preservation and modest income through dividends. Key risks include interest rate sensitivity and macroeconomic shifts affecting short-term bonds. Institutional accumulation supports confidence, but the bearish technical signal warrants caution for short-term traders.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
